

Agreement between SomaLogic and AmberGen enables use of photocleavable reagent for commercial applications of breakthrough proteomic technology

AmberGen's innovative photocleavable biotin enables current SOMAscan™ platform

Boulder, CO and Watertown, MA, November 29, 2011 – FOR IMMEDIATE RELEASE

SomaLogic, Inc. and AmberGen, Inc. announced today that they have entered into a licensing agreement whereby AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use of SomaLogic's SOMAscan™ technology platform.

The biggest constraint on successful development of a high-throughput proteomic quantitation platform is achieving sufficient sensitivity. SomaLogic's innovative SOMAmer (Slow Off-rate Modified Aptamer) protein-capture reagents and their multiplex SOMAscan technology break through this limitation.

AmberGen has developed a range of novel molecules and compounds with photocleavable linkers, including a 5-prime photocleavable biotin, a light-activated biomolecule that it has licensed to SomaLogic. "AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our SOMAscan™ platform" said Nick Saccomano, Ph.D., Chief Technology Officer at SomaLogic.

The SOMAscan™ technology platform utilizes SOMAmers to accurately screen dozens of patient samples simultaneously, allowing quantification of many specific proteins in a multiplexed, high-throughput manner. SomaLogic has thus far validated SOMAmers to a broad array of over 1000 different protein targets for use in biomarker discovery, diagnostics, and drug discovery and development.

"We look forward to exploring new applications for our photocleavable technologies with SomaLogic, as we continue to support their existing and emerging SOMAmer reagents," stated Christopher Sears, Ph.D., Chief Scientific Officer of AmberGen. "With both companies' commitment to developing tools for personalized medicine, there are ample opportunities for further collaboration."

###

About AmberGen, Inc.:

AmberGen is a privately held biomarker discovery and clinical diagnostic company based in Watertown, Massachusetts. AmberGen's proprietary molecular profiling technology enables physicians to more accurately make optimal therapeutic decisions tailored to individual patients. This is made possible by identifying unique molecular fingerprints in tumors, blood, and other biospecimens that are characteristic of specific diseases and their outcomes. AmberGen's approach combines unique patented technology in the area of proteomics, genomics, and bioinformatics.



About SomaLogic, Inc.:

SomaLogic, Inc., is a privately held biomarker discovery and clinical diagnostics company based in Boulder, Colorado. The company's mission is to use its proprietary Slow Off-rate Modified Aptamer ("SOMAmer") protein-capture reagents to develop enhanced protein analysis tools and reagents for the life sciences community, to facilitate biomarker discovery and validation for diagnostic and therapeutic applications, and to develop and commercialize clinical diagnostic products that will improve the delivery of healthcare by offering timely and precise diagnostic information to physicians and their patients. Further information about SomaLogic can be found at www.somallogic.com.

Contacts:

AmberGen, Inc.

Michele Sutherland

Director of Public Relations

P: 617-923-9999

Fax: 617-923-9980

msutherland@amberggen.com

SomaLogic, Inc.

Fintan Steele, Ph.D.

Executive Director of Communications

P: 617-816-9834

fsteele@somallogic.com